NEWS AND RESOURCES
FEATURED PROJECTS
-
-
-
April 03, 2025Share
Drug Resistance Models in Mice: Mechanisms, Establishment and Applications
-
-
-
-
February 06, 2025
Accelerating TCE Drug Development with Humanized Mouse Models
T-cell engagers (TCEs) are innovative bispecific antibodies designed to bind simultaneously to tumor-associated antigens (TAAs) and the CD3 receptor on T-cells. Several TCE drugs have already been approved, with seven bispecific antibodies targeting indications such as multiple myeloma and diffuse large B-cell lymphoma (DLBCL), focusing on markers like BCMA, GPRC5D, CD20, and CD19. In the realm of solid tumors, two TCE bispecific antibodies have received approval: Tebentafusp (Immunocore, January 2022, targeting CD3×GP100) and Tarlatamab (Amgen, May 2024, targeting CD3×DLL3). The accelerated approval of Tarlatamab has spurred increased interest in TCE bispecific antibodies for drug development in the solid tumor space. However, significant unmet clinical needs remain, especially for TCE bispecific antibodies targeting solid tumors.
To address this gap, GemPharmatech has established a comprehensive preclinical pharmacology and efficacy evaluation platform, offering a range of in vivo tumor models to support the development of TCE-based therapies.
-
-
-
-
January 17, 2025
Mouse Models for Studying Anti-PD-1 Resistance
-
-
-
News
-
September 13, 2023
GemPharmatech's Board Appoints Brandy Wilkinson, Ph.D. as its New Chief Executive Officer of GemPharmatech LLC.
GemPharmatech LLC., a leading contract research organization, announced today that its Board of Directors has appointed Dr. Brandy Wilkinson as the Chief Executive Officer of its subsidiary in the United States, effective September 12, 2023.
-
